Alnylam Pharmaceuticals (ALNY) vs. Its Peers Critical Comparison

Alnylam Pharmaceuticals (NASDAQ:ALNY) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Alnylam Pharmaceuticals to related businesses based on the strength of its analyst recommendations, risk, profitability, earnings, valuation, dividends and institutional ownership.

Valuation & Earnings

This table compares Alnylam Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alnylam Pharmaceuticals	$5.01 billion	$313.75 million	8.17
Alnylam Pharmaceuticals Competitors	$698.13 million	$10.43 million	-15.41

Alnylam Pharmaceuticals has higher revenue and earnings than its rivals. Alnylam Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Alnylam Pharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0	10	15	1	2.65
Alnylam Pharmaceuticals Competitors	9846	15131	45507	1589	2.54

Alnylam Pharmaceuticals currently has a consensus price target of $305.86, indicating a potential upside of 94.49%. As a group, “Biotechnology” companies have a potential upside of 98.10%. Given Alnylam Pharmaceuticals’ rivals higher probable upside, analysts clearly believe Alnylam Pharmaceuticals has less favorable growth aspects than its rivals.

Risk and Volatility

Alnylam Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals’ rivals have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Profitability

This table compares Alnylam Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	52.85%	155.33%	44.81%
Alnylam Pharmaceuticals Competitors	-12,359.35%	-203.09%	-30.93%

Institutional and Insider Ownership

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats its rivals on 9 of the 13 factors compared.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.